A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

These two general immune response findings, immune response at baseline and increasing immune response over time, were also ...

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...

Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

While some professors rallied to criticize the changes, federal officials called the university’s actions a “positive first ...

The Stearns County detection is the first in a Minnesota dairy herd so far this year. The same 620-cow herd also tested ...